Praxis Precision Medicines (PRAX) Expected to Announce Quarterly Earnings on Thursday

Praxis Precision Medicines (NASDAQ:PRAX) is expected to issue its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Praxis Precision Medicines to post earnings of ($3.00) per share and revenue of $0.2560 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Praxis Precision Medicines Trading Down 4.7%

Praxis Precision Medicines stock opened at $317.25 on Tuesday. The firm has a market cap of $7.99 billion, a P/E ratio of -24.59 and a beta of 2.84. Praxis Precision Medicines has a 1-year low of $26.70 and a 1-year high of $335.75. The firm has a 50-day moving average of $295.24 and a 200-day moving average of $172.18.

Insider Transactions at Praxis Precision Medicines

In other Praxis Precision Medicines news, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total value of $4,852,351.70. Following the transaction, the general counsel directly owned 20,832 shares of the company’s stock, valued at $4,022,450.88. The trade was a 54.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Lauren Mastrocola sold 13,600 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total value of $2,612,288.00. Following the completion of the sale, the insider directly owned 10,442 shares of the company’s stock, valued at $2,005,699.36. This represents a 56.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of PRAX. Kestra Advisory Services LLC bought a new position in Praxis Precision Medicines in the fourth quarter worth $348,000. Ieq Capital LLC acquired a new position in shares of Praxis Precision Medicines in the 4th quarter valued at $240,000. Martingale Asset Management L P acquired a new position in shares of Praxis Precision Medicines in the 4th quarter valued at $311,000. EntryPoint Capital LLC bought a new position in shares of Praxis Precision Medicines during the 4th quarter worth about $261,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Praxis Precision Medicines by 1,668.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,404 shares of the company’s stock valued at $233,000 after acquiring an additional 4,155 shares in the last quarter. Institutional investors own 67.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PRAX. Needham & Company LLC lifted their price objective on Praxis Precision Medicines from $460.00 to $510.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Citigroup reissued a “conviction-buy” rating on shares of Praxis Precision Medicines in a research report on Tuesday, December 30th. UBS Group set a $750.00 target price on shares of Praxis Precision Medicines in a research report on Monday, December 15th. Jefferies Financial Group reiterated a “buy” rating and set a $450.00 price target (up previously from $300.00) on shares of Praxis Precision Medicines in a research report on Tuesday, December 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $1,200.00 price objective (up from $450.00) on shares of Praxis Precision Medicines in a research report on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Praxis Precision Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $536.06.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.